MedPath

Phentermine

Generic Name
Phentermine
Brand Names
Adipex-P, Lomaira, Qsymia
Drug Type
Small Molecule
Chemical Formula
C10H15N
CAS Number
122-09-8
Unique Ingredient Identifier
C045TQL4WP

Overview

Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug. It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with fenfluramine and dexfenfluramine was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers. Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to obtain the desired effect.

Background

Phentermine is a sympathomimetic amine anorectic agent and it was introduced in 1959 as part of an anti-obesity combination drug. It is chemically related to amphetamine and it is commonly referred to as an atypical amphetamine. Phentermine has not been reported an addictive potential which allows this agent to be classified under the Schedule IV drugs (low abuse potential). Phentermine was FDA approved for short-term weight management in 1959 and it became widely used in 1960. This initial product, formed by the combination of phentermine with fenfluramine and dexfenfluramine was discontinued after finding several reports of abnormal valves in nearly 30% of the consumers. Later on, phentermine was approved alone and in combination with topiramate in 2012 as a new alternative that required lower doses of phentermine to obtain the desired effect.

Indication

Phentermine is indicated, alone or in combination with topiramate, as a short-term adjunct, not pass a few weeks, in a regimen of weight reduction based on exercise, behavioral modifications and caloric restriction in the management of exogenous obesity for patients with an initial body mass index (BMI) greater than 30 kg/m2 or greater than 27 kg/m2 in presence of other risk factors such as controller hypertension, diabetes or hyperlipidemia. Exogenous obesity is considered when the overweight is caused by consuming more food than the person activity level warrants. This condition commonly causes an increase in fat storage. It is an epidemic condition in the United States where over two-thirds of adults are overweight or obese and one in three Americans is obese. In the world, the incidence of obesity has nearly doubled.

Associated Conditions

  • Obesity

FDA Approved Products

Phentermine Resin ER
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:30 mg in 1 1
Approved: 2017/04/07
NDC:0527-1366
Phentermine Resin ER
Manufacturer:Lannett Company, Inc.
Route:ORAL
Strength:15 mg in 1 1
Approved: 2017/04/07
NDC:0527-1398

Singapore Approved Products

DUROMINE CAPSULE 15 mg
Manufacturer:Douglas Manuafacturing Ltd
Form:CAPSULE
Strength:15 mg
Online:Yes
Approved: 1988/05/16
Approval:SIN01255P
DUROMINE CAPSULE 30 mg
Manufacturer:Douglas Manufacturing Ltd
Form:CAPSULE
Strength:30 mg
Online:Yes
Approved: 1988/05/16
Approval:SIN01256P
PANBESY CAPSULE 30 mg
Manufacturer:OSMOPHARM SA, Tjoapack Netherlands B.V. (Primary Packager)
Form:CAPSULE
Strength:30 mg
Online:Yes
Approved: 1990/10/09
Approval:SIN05113P
PANBESY CAPSULE 15 MG
Manufacturer:OSMOPHARM SA, Tjoapack Netherlands B.V (Primary Packager)
Form:CAPSULE
Strength:15 mg
Online:Yes
Approved: 1991/01/07
Approval:SIN05315P

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

© Copyright 2025. All Rights Reserved by MedPath